清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Is This the Last Requiem for Simtuzumab?

作者
Peter Fickert
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:69 (2): 476-479 被引量:19
标识
DOI:10.1002/hep.30309
摘要

SEE ARTICLE ON PAGE 684 “Blessed is he who expects nothing, for he shall never be disappointed.” Alexander Pope In modern hepatology we have sung the song for the advent of effective antifibrotic drugs for decades, recalling the line of a masterpiece of the late Leonard Cohen, “a million candles burning for the help that never came.” We realize but hardly accept that most likely such drugs will not work without resolving the causative problem of a liver disease such as viral hepatitis. In liver diseases with so far unknown etiology, as in primary sclerosing cholangitis (PSC), the task of successful antifibrotic treatment will be pursued even harder. Lysyl oxidase‐like protein 2 (LOXL2) is a member of the large and diverse LOX and LOXL family that promotes stabilization of the extracellular matrix, chemotaxis, cell growth, and cell mobility and may also be engaged in the regulation of bile duct permeability.1 Induction of LOXL2 activity was demonstrated in fibrotic liver diseases.5 Therefore, targeting LOXL2 with the monoclonal humanized antibody simtuzumab could potentially have antifibrotic effects, seal leaky bile ducts, and, by inhibiting epithelial–mesenchymal transition, prevent cholangiocarcinoma. All of these potential benefits would make simtuzumab an ideal compound for the treatment of PSC patients. However, the carefully performed placebo‐controlled phase 2b trial of simtuzumab presented by Muir et al. in this issue of hepatology failed to show any clinical benefit. Simtuzumab administrated in two different doses over 96 weeks surprisingly did not even show an effect on liver fibrosis, as determined with various tests including measurement of hepatic collagen content.6 Thus, the list of studies where an anti‐LOXL2 strategy with simtuzumab in different diseases failed is growing. These studies, including liver fibrosis due to chronic hepatitis C or nonalcoholic steatohepatitis, pancreas cancer, and lung fibrosis, provided negative results despite successful preclinical studies with antimouse/rat‐LOXL2 antibodies in various animal models for such diseases.7 Now, with the current negative results in hand, one might hubristically debate whether it had been prudent to directly go for a phase 2b design and skip a phase 2a trial in PSC patients. The reasons that simtuzumab did not measure up to its expectations in the present PSC study remain enigmatic and could be numerous. (1) Simtuzumab does not reach the region where it should act; however, we do not even know whether such a region should be extracellular or intracellular. This could be related to a lack of sufficient tissue penetration or to rapid clearance from the portal field or space of Disse. Alternatively, the compound might also have been degraded or bound by unknown human‐specific proteins. Unfortunately, there was no pharmacodynamic and pharmacokinetic assay available to assess whether LOXL2 indeed was effectively inhibited in PSC livers, which might have helped to resolve this question. (2) The antibody is not antifibrotic in men because non‐LOXL2 proteins of the large family of LOXL enzymes might have interfered with selective allosteric target inhibition by simtuzumab. (3) The positive experimental results from testing a monoclonal anti‐LOXL2 antibody with high affinity for mouse LOXL2 in Mdr2 (Abcb4) knockout mice and 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine‐fed mice may not be representative of human PSC for a number of reasons, including the use of different drugs in mice and humans and different dynamics of fibrosis between humans and rodents. (4) Potential problems in the current study design include erroneous assumptions in regard to progress of liver fibrosis in PSC, wrong chosen time points of starting such a drug in patients with already advanced and fixed liver fibrosis, drug dosing, and treatment duration. (5) The hypothesis that an antifibrotic drug might help in PSC may be wrong! In this respect one might recall the negative results of colchicine treatment in PSC.11 Of note, single antifibrotic treatment strategies in PSC could even perpetuate cholangitis and pericholangitis because typically observed periductal fibrosis may also represent in part a wound healing process of the bile duct in PSC. Thus, from a theoretical point of view, inhibiting liver fibrosis, more specifically periductal fibrosis in PSC, may represent a double‐edged sword: saving the liver parenchyma but injuring the bile ducts and portal fields. Well‐designed and carefully performed clinical trials should be undoubtedly published in high‐ranked journals such as hepatology even if results are negative. Beyond that, the current study by Muir et al. provides key valuable clinical information about PSC and useful advice, in particular pointing to some pivotal questions. This study again demonstrates that serum alkaline phosphatase (ALP) levels are important in PSC because 34% of patients with ALP >324 U/L had clinical events, indicating that ALP serum levels should be used as a stratification factor for clinical trials. Again, liver stiffness was shown to be a meaningful clinical parameter, and an increase >8.7 kPa as measured by transient elastography was indicative of a 6‐fold increase of clinical events in PSC patients. There are numerous additional important clinical findings of this study that cannot be discussed in detail here but certainly will trigger important responses and letters from the readers! We also learn from this study that we need to continue the discussion of repeated liver biopsies as being pivotal for high‐quality PSC trials. Personally, I think the answer is yes as far as we lack equally valid and reliable noninvasive markers. In addition, we still will gain important information from repeated liver biopsies in PSC patients under verum or placebo treatment, obtaining liver tissue for detailed investigations beyond liver histology (e.g., omics). One of the hard tasks in developing agents or useful combinations of drugs for the treatment of PSC still seems to be the selection of well‐suited surrogate endpoints because the need for liver transplantation or death due to liver failure occur in unsteady intervals in PSC patients. Even so, the risk will remain that we may perform PSC treatment trials of increasing quality by using appropriate surrogate parameters but still with drugs that do not help at all or fail in our specific study population. It is likely that the comprehensible goal of precision treatment with one single drug in PSC currently is an overambitious or unrealistic one because we still do not know the cause of PSC. Currently, “PSC” remains a kind of umbrella term and from a clinical perspective a mixed bag. Despite numerous promising approaches, we currently should accept that a successful one‐pill strategy would remain unlikely for such a complex disease like PSC. Rather, stage‐adapted combination medical therapy is likely to emerge, as already established in chronic congestive heart failure. The highly dynamic development of drugs and treatment strategies for PSC with more than 40 ongoing studies registered at ClinicalTrials.gov underscores the importance for the International PSC Study Group to discuss and validate appropriate study design and to coordinate clinical testing for more rapid progress and best benefit for our patients. Consequently, we should intensify our combined efforts to identify the etiology of PSC, integrating transformative technologies with partners from both different scientific disciplines and industry. In addition, we currently should aim to develop a conceptual framework for a game‐changing tailored combination therapy in PSC–inflammatory bowel disease (IBD) (Fig. 1). Special emphasis should be given to the fact that PSC patients in an early phase of disease have most likely different medical needs than those in an advanced or late stage. It will be interesting to see whether in the future there will be a place for anti‐LOXL2 strategies beside simtuzumab in the treatment of PSC.Figure 1: Conceptual framework for future stage‐adapted personalized PSC treatment. Precision treatment of PSC with one single drug currently seems to be unrealistic due to the unknown etiology of PSC. This figure depicts a conceptual framework as a model for further discussion to design potentially effective combination therapies in PSC in analogy to congestive heart failure. Specific drugs or interventions may be more suitable in early PSC (e.g., budesonide, fecal microbiota transplant), whereas others may better fit late PSC (e.g., Na+–taurocholate cotransporting polypeptide blockers, liver transplantation). Special emphasis should be given to improved understanding of pathogenesis and treatment of PSC‐IBD, which is obviously different from “classical ulcerative colitis.” Abbreviations: 5‐ASA, 5‐aminosalicylic acid; ASBT, apical sodium‐dependent bile acid transporter; ATRA, all‐trans retinoic acid; FMT, fecal microbiota transplant; LTX, liver transplantation; NTCP, Na+–taurocholate cotransporting polypeptide; OCA, obeticholic acid; SASP, sulfasalazine; UDCA, ursodeoxycholic acid; VAP1, vascular adhesion protein 1.Potential conflict of interest Nothing to report.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tracy完成签到,获得积分10
1秒前
zwlei完成签到,获得积分10
4秒前
腼腆的雪珊完成签到,获得积分10
5秒前
热情的衬衫完成签到,获得积分10
11秒前
xingsixs完成签到,获得积分10
13秒前
危机的白凡完成签到,获得积分10
26秒前
徐伟业完成签到 ,获得积分10
36秒前
RetchieLi完成签到,获得积分10
36秒前
41秒前
无限幻枫发布了新的文献求助10
47秒前
眼睛大的向彤完成签到,获得积分10
49秒前
俭朴映寒完成签到,获得积分10
57秒前
汉堡包的应助被bluemoon采纳,获得10
58秒前
59秒前
王磊磊0811发布了新的文献求助10
1分钟前
害羞傲安完成签到,获得积分10
1分钟前
外向夜阑完成签到,获得积分10
1分钟前
LINDENG2004完成签到 ,获得积分10
1分钟前
年轻千萍完成签到,获得积分10
1分钟前
睡不醒完成签到 ,获得积分10
1分钟前
简单的不平完成签到,获得积分10
1分钟前
一个爱打乒乓球的彪完成签到 ,获得积分10
2分钟前
单身的涫完成签到,获得积分10
2分钟前
闪闪小凡完成签到,获得积分10
2分钟前
孝顺的冰姬完成签到,获得积分10
2分钟前
拼搏愚志完成签到,获得积分10
2分钟前
田田完成签到 ,获得积分10
2分钟前
无情幻巧完成签到,获得积分10
2分钟前
Lucas的应助被科研通管家采纳,获得10
2分钟前
2分钟前
Alvin完成签到 ,获得积分10
3分钟前
含蓄的觅波完成签到,获得积分10
3分钟前
内向的紫槐完成签到,获得积分10
3分钟前
Edward完成签到,获得积分10
3分钟前
辛勤的涵菡完成签到,获得积分10
3分钟前
Maestro_S的应助被初景采纳,获得10
3分钟前
自由乌冬面完成签到,获得积分10
3分钟前
从容棉花糖完成签到,获得积分10
3分钟前
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370